InFlectis BioScience, headquartered in France, is a clinical-stage pharmaceutical discovery company that specializes in developing small chemical drug candidates with multifunctional properties. These candidates exhibit modulation activity on the PP1c/PPP1R15A phosphatase complex and act as GluN2B-containing NMDAR antagonists for the treatment of neuromuscular diseases. The main focus of InFlectis BioScience is advancing IFB-088 (icerguastat), an orally available small molecule, to treat Charcot-Marie-Tooth and Multiple Sclerosis. Currently, a phase 2 clinical trial involving IFB-088 in bulbar-onset ALS patients is underway in Europe, with ongoing patient recruitment (NCT05508074). IFB-088 is also poised to enter a phase 2 clinical trial for Charcot-Marie-Tooth.